nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—EPHA3—cleft lip	0.722	1	CbGaD
Dasatinib—EPHB1—tongue—cleft lip	0.00391	0.0517	CbGeAlD
Dasatinib—SRC—periosteum—cleft lip	0.0031	0.041	CbGeAlD
Dasatinib—CSF1R—periosteum—cleft lip	0.00279	0.0369	CbGeAlD
Dasatinib—EPHB1—mouth—cleft lip	0.00263	0.0347	CbGeAlD
Dasatinib—EPHA4—tongue—cleft lip	0.00177	0.0234	CbGeAlD
Dasatinib—MYT1—head—cleft lip	0.00142	0.0188	CbGeAlD
Dasatinib—STAT5B—embryo—cleft lip	0.00139	0.0184	CbGeAlD
Dasatinib—LIMK2—mouth—cleft lip	0.00137	0.0182	CbGeAlD
Dasatinib—EPHB2—telencephalon—cleft lip	0.00125	0.0165	CbGeAlD
Dasatinib—SRMS—telencephalon—cleft lip	0.00122	0.0162	CbGeAlD
Dasatinib—SIK1—mouth—cleft lip	0.0012	0.0159	CbGeAlD
Dasatinib—EPHA4—mouth—cleft lip	0.00119	0.0157	CbGeAlD
Dasatinib—ERBB3—mouth—cleft lip	0.00118	0.0156	CbGeAlD
Dasatinib—STAT5B—telencephalon—cleft lip	0.00113	0.015	CbGeAlD
Dasatinib—MAPK14—mouth—cleft lip	0.0011	0.0145	CbGeAlD
Dasatinib—SIK3—telencephalon—cleft lip	0.00102	0.0135	CbGeAlD
Dasatinib—EPHB3—embryo—cleft lip	0.00101	0.0134	CbGeAlD
Dasatinib—EPHB1—head—cleft lip	0.000948	0.0125	CbGeAlD
Dasatinib—CSK—embryo—cleft lip	0.000944	0.0125	CbGeAlD
Dasatinib—EPHA5—telencephalon—cleft lip	0.000927	0.0123	CbGeAlD
Dasatinib—TNK2—telencephalon—cleft lip	0.000891	0.0118	CbGeAlD
Dasatinib—EPHA4—embryo—cleft lip	0.000847	0.0112	CbGeAlD
Dasatinib—ERBB3—embryo—cleft lip	0.000838	0.0111	CbGeAlD
Dasatinib—SIK2—head—cleft lip	0.000838	0.0111	CbGeAlD
Dasatinib—EPHB3—telencephalon—cleft lip	0.000824	0.0109	CbGeAlD
Dasatinib—PKMYT1—head—cleft lip	0.000816	0.0108	CbGeAlD
Dasatinib—MAPK14—embryo—cleft lip	0.000781	0.0103	CbGeAlD
Dasatinib—EPHB2—head—cleft lip	0.000779	0.0103	CbGeAlD
Dasatinib—FGR—embryo—cleft lip	0.000777	0.0103	CbGeAlD
Dasatinib—SRMS—head—cleft lip	0.000762	0.0101	CbGeAlD
Dasatinib—HCK—telencephalon—cleft lip	0.000758	0.01	CbGeAlD
Dasatinib—TXK—head—cleft lip	0.000754	0.00998	CbGeAlD
Dasatinib—EPHA8—head—cleft lip	0.000747	0.00988	CbGeAlD
Dasatinib—JAK2—embryo—cleft lip	0.000735	0.00972	CbGeAlD
Dasatinib—FYN—embryo—cleft lip	0.000725	0.00959	CbGeAlD
Dasatinib—KIT—mouth—cleft lip	0.00072	0.00952	CbGeAlD
Dasatinib—STAT5B—head—cleft lip	0.000706	0.00934	CbGeAlD
Dasatinib—SIK1—telencephalon—cleft lip	0.000696	0.0092	CbGeAlD
Dasatinib—EPHA4—telencephalon—cleft lip	0.000689	0.00911	CbGeAlD
Dasatinib—ERBB3—telencephalon—cleft lip	0.000682	0.00902	CbGeAlD
Dasatinib—MAP3K2—telencephalon—cleft lip	0.000675	0.00893	CbGeAlD
Dasatinib—EPHA3—head—cleft lip	0.000653	0.00863	CbGeAlD
Dasatinib—PDGFRA—embryo—cleft lip	0.000642	0.00849	CbGeAlD
Dasatinib—MAPK14—telencephalon—cleft lip	0.000635	0.0084	CbGeAlD
Dasatinib—SIK3—head—cleft lip	0.000635	0.0084	CbGeAlD
Dasatinib—SRC—embryo—cleft lip	0.000629	0.00832	CbGeAlD
Dasatinib—EPHB4—telencephalon—cleft lip	0.000602	0.00796	CbGeAlD
Dasatinib—JAK2—telencephalon—cleft lip	0.000598	0.00791	CbGeAlD
Dasatinib—ZAK—head—cleft lip	0.00059	0.00781	CbGeAlD
Dasatinib—FYN—telencephalon—cleft lip	0.000589	0.0078	CbGeAlD
Dasatinib—EPHA5—head—cleft lip	0.000577	0.00764	CbGeAlD
Dasatinib—MAP4K5—telencephalon—cleft lip	0.000576	0.00762	CbGeAlD
Dasatinib—LYN—head—cleft lip	0.000574	0.0076	CbGeAlD
Dasatinib—BMPR1B—head—cleft lip	0.000566	0.00748	CbGeAlD
Dasatinib—MAP3K19—head—cleft lip	0.000566	0.00748	CbGeAlD
Dasatinib—CSF1R—embryo—cleft lip	0.000565	0.00747	CbGeAlD
Dasatinib—TNK2—head—cleft lip	0.000555	0.00734	CbGeAlD
Dasatinib—EPHB6—telencephalon—cleft lip	0.00055	0.00728	CbGeAlD
Dasatinib—YES1—telencephalon—cleft lip	0.000532	0.00704	CbGeAlD
Dasatinib—PDGFRA—telencephalon—cleft lip	0.000522	0.0069	CbGeAlD
Dasatinib—TESK1—head—cleft lip	0.000522	0.0069	CbGeAlD
Dasatinib—STK36—head—cleft lip	0.000513	0.00679	CbGeAlD
Dasatinib—EPHB3—head—cleft lip	0.000513	0.00679	CbGeAlD
Dasatinib—KIT—embryo—cleft lip	0.000513	0.00679	CbGeAlD
Dasatinib—SRC—telencephalon—cleft lip	0.000512	0.00677	CbGeAlD
Dasatinib—PDGFRB—embryo—cleft lip	0.000501	0.00663	CbGeAlD
Dasatinib—LIMK2—head—cleft lip	0.000496	0.00657	CbGeAlD
Dasatinib—STK35—head—cleft lip	0.000481	0.00636	CbGeAlD
Dasatinib—CSK—head—cleft lip	0.000478	0.00632	CbGeAlD
Dasatinib—HCK—head—cleft lip	0.000472	0.00624	CbGeAlD
Dasatinib—MAP2K5—telencephalon—cleft lip	0.000471	0.00623	CbGeAlD
Dasatinib—CSF1R—telencephalon—cleft lip	0.000459	0.00608	CbGeAlD
Dasatinib—ABL1—embryo—cleft lip	0.000447	0.00591	CbGeAlD
Dasatinib—RIPK2—head—cleft lip	0.000444	0.00587	CbGeAlD
Dasatinib—SIK1—head—cleft lip	0.000433	0.00573	CbGeAlD
Dasatinib—EPHA4—head—cleft lip	0.000429	0.00567	CbGeAlD
Dasatinib—ERBB3—head—cleft lip	0.000425	0.00562	CbGeAlD
Dasatinib—MAP3K2—head—cleft lip	0.00042	0.00556	CbGeAlD
Dasatinib—KIT—telencephalon—cleft lip	0.000417	0.00552	CbGeAlD
Dasatinib—PDGFRB—telencephalon—cleft lip	0.000407	0.00539	CbGeAlD
Dasatinib—MAPK14—head—cleft lip	0.000395	0.00523	CbGeAlD
Dasatinib—FGR—head—cleft lip	0.000394	0.00521	CbGeAlD
Dasatinib—FMO3—head—cleft lip	0.00038	0.00503	CbGeAlD
Dasatinib—CYP1A1—mouth—cleft lip	0.000375	0.00496	CbGeAlD
Dasatinib—JAK2—head—cleft lip	0.000372	0.00492	CbGeAlD
Dasatinib—EPHA2—head—cleft lip	0.000368	0.00486	CbGeAlD
Dasatinib—FYN—head—cleft lip	0.000367	0.00486	CbGeAlD
Dasatinib—ABL1—telencephalon—cleft lip	0.000363	0.0048	CbGeAlD
Dasatinib—MAP3K3—head—cleft lip	0.000359	0.00474	CbGeAlD
Dasatinib—MAP4K5—head—cleft lip	0.000359	0.00474	CbGeAlD
Dasatinib—EPHB6—head—cleft lip	0.000343	0.00453	CbGeAlD
Dasatinib—YES1—head—cleft lip	0.000331	0.00438	CbGeAlD
Dasatinib—PDGFRA—head—cleft lip	0.000325	0.0043	CbGeAlD
Dasatinib—SRC—head—cleft lip	0.000319	0.00422	CbGeAlD
Dasatinib—CYP1B1—telencephalon—cleft lip	0.000308	0.00407	CbGeAlD
Dasatinib—MAP2K5—head—cleft lip	0.000293	0.00388	CbGeAlD
Dasatinib—CSF1R—head—cleft lip	0.000286	0.00378	CbGeAlD
Dasatinib—KIT—head—cleft lip	0.00026	0.00344	CbGeAlD
Dasatinib—PDGFRB—head—cleft lip	0.000254	0.00336	CbGeAlD
Dasatinib—ABCG2—telencephalon—cleft lip	0.000229	0.00303	CbGeAlD
Dasatinib—ABL1—head—cleft lip	0.000226	0.00299	CbGeAlD
Dasatinib—CYP1B1—head—cleft lip	0.000192	0.00253	CbGeAlD
Dasatinib—ABCB1—embryo—cleft lip	0.000139	0.00184	CbGeAlD
Dasatinib—CYP1A1—head—cleft lip	0.000135	0.00179	CbGeAlD
Dasatinib—ABCB1—telencephalon—cleft lip	0.000113	0.00149	CbGeAlD
Dasatinib—ABCB1—head—cleft lip	7.03e-05	0.00093	CbGeAlD
Dasatinib—RIPK2—Signaling Pathways—FGFR1—cleft lip	5.9e-06	2.92e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—NOS3—cleft lip	5.88e-06	2.91e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—FGF2—cleft lip	5.88e-06	2.91e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—SLC19A1—cleft lip	5.87e-06	2.9e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—FGFR1—cleft lip	5.83e-06	2.88e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—FGFR2—cleft lip	5.79e-06	2.86e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PTCH1—cleft lip	5.79e-06	2.86e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—FGF2—cleft lip	5.78e-06	2.86e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—FGF10—cleft lip	5.78e-06	2.86e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—FGFR2—cleft lip	5.78e-06	2.86e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—FGF3—cleft lip	5.74e-06	2.84e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTCH1—cleft lip	5.72e-06	2.83e-05	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—NOS3—cleft lip	5.71e-06	2.82e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—NOS3—cleft lip	5.7e-06	2.82e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—MTHFR—cleft lip	5.7e-06	2.82e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—FGF3—cleft lip	5.66e-06	2.8e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—FGFR2—cleft lip	5.65e-06	2.8e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—FGFR3—cleft lip	5.65e-06	2.79e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—FGFR2—cleft lip	5.63e-06	2.78e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—FGF9—cleft lip	5.6e-06	2.77e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—FGFR2—cleft lip	5.59e-06	2.76e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—FGFR3—cleft lip	5.58e-06	2.76e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FGF8—cleft lip	5.58e-06	2.76e-05	CbGpPWpGaD
Dasatinib—CSK—Disease—MYC—cleft lip	5.57e-06	2.75e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—FGFR2—cleft lip	5.57e-06	2.75e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—FGF3—cleft lip	5.54e-06	2.74e-05	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—MYC—cleft lip	5.53e-06	2.74e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—FGFR1—cleft lip	5.52e-06	2.73e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—FGF9—cleft lip	5.52e-06	2.73e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—FGFR3—cleft lip	5.51e-06	2.72e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—FGF10—cleft lip	5.46e-06	2.7e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—FGF3—cleft lip	5.45e-06	2.7e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—FGF2—cleft lip	5.43e-06	2.68e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—FGF2—cleft lip	5.43e-06	2.68e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—FGF2—cleft lip	5.42e-06	2.68e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—FGF9—cleft lip	5.4e-06	2.67e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—FGFR1—cleft lip	5.4e-06	2.67e-05	CbGpPWpGaD
Dasatinib—STAT5B—Disease—MYC—cleft lip	5.39e-06	2.67e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—FGFR1—cleft lip	5.38e-06	2.66e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—FGFR2—cleft lip	5.36e-06	2.65e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—NOS3—cleft lip	5.35e-06	2.65e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGF7—cleft lip	5.35e-06	2.65e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SPRY2—cleft lip	5.35e-06	2.65e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—FGFR2—cleft lip	5.33e-06	2.64e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—FGF10—cleft lip	5.33e-06	2.64e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—FGF9—cleft lip	5.32e-06	2.63e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—FGFR2—cleft lip	5.29e-06	2.62e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—FGFR1—cleft lip	5.27e-06	2.61e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—NOS3—cleft lip	5.25e-06	2.6e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—FGF3—cleft lip	5.25e-06	2.6e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—FGFR1—cleft lip	5.25e-06	2.59e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—FGFR3—cleft lip	5.21e-06	2.58e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—FGFR1—cleft lip	5.21e-06	2.57e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—FGF2—cleft lip	5.2e-06	2.57e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—FGFR1—cleft lip	5.19e-06	2.57e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—FGF3—cleft lip	5.18e-06	2.56e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—FGF10—cleft lip	5.16e-06	2.55e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—FGF2—cleft lip	5.16e-06	2.55e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—FGFR2—cleft lip	5.14e-06	2.54e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—MTHFR—cleft lip	5.13e-06	2.54e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—FGF9—cleft lip	5.12e-06	2.53e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—FGF10—cleft lip	5.11e-06	2.53e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—FGFR3—cleft lip	5.1e-06	2.52e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—FGFR3—cleft lip	5.09e-06	2.52e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—FGF9—cleft lip	5.05e-06	2.5e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTCH1—cleft lip	5.01e-06	2.48e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—FGFR1—cleft lip	5e-06	2.47e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—FGFR3—cleft lip	4.98e-06	2.46e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—FGFR1—cleft lip	4.97e-06	2.46e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—FGFR3—cleft lip	4.96e-06	2.45e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—MTHFR—cleft lip	4.95e-06	2.45e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGF8—cleft lip	4.94e-06	2.44e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—FGFR1—cleft lip	4.93e-06	2.44e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—FGFR3—cleft lip	4.92e-06	2.43e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—FGFR3—cleft lip	4.9e-06	2.42e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—FGFR2—cleft lip	4.9e-06	2.42e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—FGFR2—cleft lip	4.89e-06	2.42e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—TCN2—cleft lip	4.87e-06	2.41e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—FGF2—cleft lip	4.8e-06	2.37e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—FGFR1—cleft lip	4.79e-06	2.37e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—FGFR3—cleft lip	4.72e-06	2.33e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—FGF10—cleft lip	4.72e-06	2.33e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—MTHFR—cleft lip	4.7e-06	2.33e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—FGFR3—cleft lip	4.7e-06	2.32e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—SLC19A1—cleft lip	4.69e-06	2.32e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—FGFR3—cleft lip	4.66e-06	2.3e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—FGF10—cleft lip	4.65e-06	2.3e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—FGFR2—cleft lip	4.63e-06	2.29e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—FGF2—cleft lip	4.61e-06	2.28e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—FGF2—cleft lip	4.6e-06	2.28e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—FGFR1—cleft lip	4.57e-06	2.26e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—FGF10—cleft lip	4.56e-06	2.25e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—FGFR1—cleft lip	4.55e-06	2.25e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FGF3—cleft lip	4.54e-06	2.24e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—FGFR3—cleft lip	4.53e-06	2.24e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	4.49e-06	2.22e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—FGF10—cleft lip	4.48e-06	2.22e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—MTR—cleft lip	4.47e-06	2.21e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTCH1—cleft lip	4.43e-06	2.19e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FGF9—cleft lip	4.43e-06	2.19e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—FGFR2—cleft lip	4.38e-06	2.16e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—FGF2—cleft lip	4.36e-06	2.16e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—FGFR1—cleft lip	4.32e-06	2.14e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—FGFR3—cleft lip	4.32e-06	2.14e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—FGF10—cleft lip	4.32e-06	2.14e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—FGF2—cleft lip	4.31e-06	2.13e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—FGFR3—cleft lip	4.3e-06	2.13e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—FGFR2—cleft lip	4.28e-06	2.12e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—MYC—cleft lip	4.27e-06	2.11e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—FGF10—cleft lip	4.26e-06	2.11e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—FGF2—cleft lip	4.26e-06	2.1e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—NOS3—cleft lip	4.25e-06	2.1e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—MTR—cleft lip	4.22e-06	2.09e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—TYMS—cleft lip	4.2e-06	2.08e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—NOS3—cleft lip	4.2e-06	2.08e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—FGFR2—cleft lip	4.14e-06	2.05e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—MTHFR—cleft lip	4.12e-06	2.04e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—FGFR2—cleft lip	4.1e-06	2.03e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—FGFR3—cleft lip	4.08e-06	2.02e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—FGFR1—cleft lip	4.08e-06	2.02e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—FGF2—cleft lip	4.03e-06	1.99e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGF3—cleft lip	4.02e-06	1.99e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—FGFR1—cleft lip	3.99e-06	1.97e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—NOS3—cleft lip	3.97e-06	1.96e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—FGF2—cleft lip	3.94e-06	1.95e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—FGF2—cleft lip	3.93e-06	1.94e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGF9—cleft lip	3.92e-06	1.94e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—MYC—cleft lip	3.9e-06	1.93e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—NOS3—cleft lip	3.89e-06	1.92e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TCN2—cleft lip	3.89e-06	1.92e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—FGFR1—cleft lip	3.86e-06	1.91e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—FGFR3—cleft lip	3.86e-06	1.91e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—FGF2—cleft lip	3.85e-06	1.9e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—FGF2—cleft lip	3.83e-06	1.89e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—TYMS—cleft lip	3.83e-06	1.89e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—FGFR1—cleft lip	3.82e-06	1.89e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—FGF2—cleft lip	3.8e-06	1.88e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—FGF2—cleft lip	3.79e-06	1.87e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—FGFR2—cleft lip	3.79e-06	1.87e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—MYC—cleft lip	3.78e-06	1.87e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—FGFR3—cleft lip	3.77e-06	1.86e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—NOS3—cleft lip	3.75e-06	1.85e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—FGFR2—cleft lip	3.73e-06	1.85e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FGF10—cleft lip	3.73e-06	1.85e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—MTHFR—cleft lip	3.67e-06	1.82e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—FGFR2—cleft lip	3.66e-06	1.81e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—FGFR3—cleft lip	3.65e-06	1.81e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—FGF2—cleft lip	3.65e-06	1.8e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—MTHFR—cleft lip	3.65e-06	1.8e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—FGF2—cleft lip	3.63e-06	1.79e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC19A1—cleft lip	3.62e-06	1.79e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—FGFR3—cleft lip	3.61e-06	1.79e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—FGF2—cleft lip	3.6e-06	1.78e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—FGFR2—cleft lip	3.6e-06	1.78e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—NOS3—cleft lip	3.58e-06	1.77e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—MYC—cleft lip	3.55e-06	1.75e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—FGFR1—cleft lip	3.53e-06	1.75e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—FGF2—cleft lip	3.5e-06	1.73e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—FGFR1—cleft lip	3.48e-06	1.72e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—FGFR2—cleft lip	3.47e-06	1.71e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—NOS3—cleft lip	3.45e-06	1.71e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—FGFR2—cleft lip	3.42e-06	1.69e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—FGFR1—cleft lip	3.41e-06	1.68e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTR—cleft lip	3.37e-06	1.67e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—FGFR1—cleft lip	3.35e-06	1.66e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—MTHFR—cleft lip	3.34e-06	1.65e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—FGF2—cleft lip	3.34e-06	1.65e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—FGFR3—cleft lip	3.34e-06	1.65e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—FGF2—cleft lip	3.33e-06	1.64e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGF10—cleft lip	3.31e-06	1.63e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—NOS3—cleft lip	3.29e-06	1.63e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—FGFR3—cleft lip	3.29e-06	1.63e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—NOS3—cleft lip	3.28e-06	1.62e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—FGFR1—cleft lip	3.23e-06	1.6e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—FGFR3—cleft lip	3.22e-06	1.59e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—FGFR1—cleft lip	3.19e-06	1.58e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—FGFR3—cleft lip	3.17e-06	1.57e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—FGF2—cleft lip	3.15e-06	1.56e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—FGFR3—cleft lip	3.05e-06	1.51e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—FGFR3—cleft lip	3.01e-06	1.49e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TCN2—cleft lip	3e-06	1.48e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FGFR2—cleft lip	3e-06	1.48e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—FGF2—cleft lip	2.98e-06	1.47e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—NOS3—cleft lip	2.94e-06	1.45e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—FGF2—cleft lip	2.91e-06	1.44e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—NOS3—cleft lip	2.87e-06	1.42e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—FGF2—cleft lip	2.82e-06	1.39e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—MYC—cleft lip	2.82e-06	1.39e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—FGF2—cleft lip	2.79e-06	1.38e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FGFR1—cleft lip	2.79e-06	1.38e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NOS3—cleft lip	2.78e-06	1.38e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—MYC—cleft lip	2.78e-06	1.38e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—TYMS—cleft lip	2.74e-06	1.36e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTR—cleft lip	2.69e-06	1.33e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGFR2—cleft lip	2.65e-06	1.31e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FGFR3—cleft lip	2.64e-06	1.31e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—MYC—cleft lip	2.63e-06	1.3e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—TYMS—cleft lip	2.59e-06	1.28e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—FGF2—cleft lip	2.58e-06	1.28e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MYC—cleft lip	2.58e-06	1.27e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—NOS3—cleft lip	2.56e-06	1.27e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—NOS3—cleft lip	2.54e-06	1.26e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—FGF2—cleft lip	2.54e-06	1.26e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NOS3—cleft lip	2.51e-06	1.24e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—FGF2—cleft lip	2.49e-06	1.23e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MYC—cleft lip	2.49e-06	1.23e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGFR1—cleft lip	2.47e-06	1.22e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NOS3—cleft lip	2.45e-06	1.21e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—FGF2—cleft lip	2.45e-06	1.21e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NOS3—cleft lip	2.42e-06	1.19e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—MTHFR—cleft lip	2.39e-06	1.18e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—MYC—cleft lip	2.37e-06	1.17e-05	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—MYC—cleft lip	2.37e-06	1.17e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—FGF2—cleft lip	2.36e-06	1.17e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGFR3—cleft lip	2.34e-06	1.16e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—NOS3—cleft lip	2.33e-06	1.15e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—FGF2—cleft lip	2.33e-06	1.15e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NOS3—cleft lip	2.33e-06	1.15e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NOS3—cleft lip	2.3e-06	1.14e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—MYC—cleft lip	2.29e-06	1.13e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—MTHFR—cleft lip	2.26e-06	1.12e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MYC—cleft lip	2.18e-06	1.08e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—MYC—cleft lip	2.17e-06	1.07e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTR—cleft lip	2.08e-06	1.03e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—TYMS—cleft lip	2.07e-06	1.02e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FGF2—cleft lip	2.04e-06	1.01e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NOS3—cleft lip	2.01e-06	9.95e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MYC—cleft lip	1.95e-06	9.63e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—cleft lip	1.9e-06	9.42e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—cleft lip	1.84e-06	9.12e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTHFR—cleft lip	1.81e-06	8.93e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGF2—cleft lip	1.81e-06	8.93e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NOS3—cleft lip	1.78e-06	8.81e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—cleft lip	1.69e-06	8.34e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—NOS3—cleft lip	1.67e-06	8.26e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—cleft lip	1.66e-06	8.22e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TYMS—cleft lip	1.65e-06	8.16e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—cleft lip	1.63e-06	8.04e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—cleft lip	1.6e-06	7.92e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—NOS3—cleft lip	1.58e-06	7.8e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—cleft lip	1.54e-06	7.63e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—cleft lip	1.52e-06	7.53e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—cleft lip	1.44e-06	7.13e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—cleft lip	1.33e-06	6.59e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TYMS—cleft lip	1.27e-06	6.3e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NOS3—cleft lip	1.26e-06	6.23e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—cleft lip	1.18e-06	5.84e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—cleft lip	1.11e-06	5.5e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NOS3—cleft lip	1.01e-06	4.97e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NOS3—cleft lip	7.76e-07	3.84e-06	CbGpPWpGaD
